Redx Pharma (LON:REDX) Stock Price Up 31.6%

Redx Pharma Plc (LON:REDX) traded up 31.6% during trading on Tuesday . The company traded as high as GBX 16.78 ($0.21) and last traded at GBX 15 ($0.19). 1,420,136 shares changed hands during mid-day trading, an increase of 101% from the average session volume of 706,684 shares. The stock had previously closed at GBX 11.40 ($0.14).

Redx Pharma Trading Up 31.6 %

The company has a debt-to-equity ratio of 527.00, a quick ratio of 1.93 and a current ratio of 1.11. The firm has a market capitalization of £58.35 million, a P/E ratio of -150.00 and a beta of -0.53. The firm has a 50 day simple moving average of GBX 15.15 and a two-hundred day simple moving average of GBX 20.24.

Insider Activity

In other news, insider Lisa Anson acquired 399,000 shares of Redx Pharma stock in a transaction on Thursday, April 11th. The stock was acquired at an average cost of GBX 8 ($0.10) per share, with a total value of £31,920 ($40,095.47). 18.23% of the stock is currently owned by corporate insiders.

Redx Pharma Company Profile

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.